ImmunoCellular Therapeutics, Ltd. announced that its Board of Directors has appointed Mark A. Schlossberg and Gregg A. Lapointe as Board members. Mr. Schlossberg has been appointed to the Audit and Nominating & Governance Committees of the Board, and Mr. Lapointe has been appointed to the Compensation Committee of the Board. Mr. Schlossberg currently serves as Senior Vice President, General Counsel and Corporate Secretary of Impax Laboratories Inc., where he is part of the senior management team responsible for the strategic direction and financial condition of the company.

He leads the legal team and previously had responsibility for the healthcare compliance team. Prior to Impax, he served as Vice President, Associate General Counsel of Amgen Inc., where he led the legal department, and was responsible for corporate governance, securities law, licensing, mergers and acquisitions, global operations, and sales and marketing compliance. Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals Inc. He previously served as Chief Operating Officer and then as Chief Executive Officer of Sigma-Tau Pharmaceuticals Inc. and the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A.